Is high IGF-1 associated with cancer risk?

This is one of the most nuanced questions in longevity medicine. IGF-1 is a potent mitogenic hormone that stimulates cell proliferation and inhibits apoptosis. Epidemiological data show associations between higher IGF-1 levels and increased risk of prostate, breast, colorectal, and other cancers. However, these associations are strongest at persistently supraphysiologic levels above 250 to 300 ng/mL. Within the functional medicine optimal range of 120 to 200 ng/mL, the evidence for cancer risk is much less clear, while the benefits for muscle mass, metabolic health, and quality of life are well-established.

Lab Reference Library / IGF-1 Longevity & Aging

IGF-1

Q: What is the optimal IGF-1 level?

In functional medicine, the optimal IGF-1 range for adults is approximately 120 to 200 ng/mL. This represents a middle range that avoids both the sarcopenia, metabolic impairment, and quality-of-life reduction associated with IGF-1 below 100 ng/mL, and the potential cancer-promoting and cardiovascular risk associated with IGF-1 persistently above 250 to 300 ng/mL. The optimal range shifts lower with advancing age, and interpretation requires clinical context including symptoms, muscle mass, and metabolic health.

Q: What does low IGF-1 mean?

Low IGF-1 indicates reduced growth hormone axis activity from the pituitary, liver dysfunction impairing IGF-1 production, protein or caloric undernutrition, severe insulin resistance, hypothyroidism, or inflammatory illness. Symptoms include reduced muscle mass and strength, increased body fat (particularly visceral), fatigue, poor exercise recovery, reduced bone density, cognitive difficulties, and impaired immune function. In adults, low IGF-1 is associated with increased mortality and reduced quality of life.

Q: How do you naturally increase IGF-1?

The most effective natural IGF-1 stimulants are resistance training (the most potent natural stimulus for GH and IGF-1 secretion), adequate dietary protein intake (0.7 to 1.0g per pound of body weight daily; protein deficiency rapidly reduces IGF-1), optimizing sleep (70 to 80% of daily GH secretion occurs during deep sleep; improving sleep quality raises IGF-1), optimizing thyroid function (thyroid hormone is required for GH pulsatility), reducing insulin resistance, and addressing zinc and magnesium deficiency.

Q: What is the relationship between IGF-1 and growth hormone?

Growth hormone (GH) is secreted by the pituitary gland in pulses, primarily during deep sleep. GH travels to the liver and stimulates IGF-1 production. IGF-1 then mediates most of GH's anabolic and metabolic effects throughout the body, including protein synthesis, muscle growth, bone density maintenance, and fat metabolism. Because GH pulses are brief and variable while IGF-1 has a much longer half-life (12 to 15 hours), serum IGF-1 provides a much more stable and reliable reflection of overall GH axis activity than GH measurement itself.

IGF-1 · Insulin-Like Growth Factor 1 · Somatomedin C

Reference range, optimal functional medicine levels, and why IGF-1 is the primary mediator of growth hormone activity, a key longevity biomarker with a complex optimal range where both deficiency and excess accelerate aging and disease risk.

Most SearchedLongevity Marker

Standard Range (M)88 to 246 ng/mL

FM Optimal120 to 200 ng/mL

Standard Range (W)72 to 238 ng/mL

Unitsng/mL

← Back to Lab Reference Library

Category: Longevity & Aging | Also known as: Insulin-Like Growth Factor 1, Somatomedin C | Sample: Serum (fasting preferred for consistency)

1. What This Test Measures

IGF-1 (Insulin-Like Growth Factor 1), historically called Somatomedin C, is a peptide hormone produced primarily in the liver in response to stimulation by growth hormone (GH) from the pituitary gland. IGF-1 mediates most of GH's anabolic and metabolic effects throughout the body and serves as the standard clinical proxy for overall growth hormone axis activity.

The GH-IGF-1 axis operates as follows: the hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates the pituitary to release GH in distinct pulses (primarily during deep sleep and after exercise). GH then acts on hepatic receptors to stimulate IGF-1 production. IGF-1 circulates in the blood largely bound to IGF-binding proteins (particularly IGFBP-3), which extend its half-life to 12 to 15 hours, making serum IGF-1 a far more stable and reproducible measure of GH axis activity than GH itself (which has a half-life of only 20 to 30 minutes and is highly pulsatile).

IGF-1 acts on virtually every organ system through its own receptor (IGF-1R), which is closely related to the insulin receptor. Its primary roles include:

Promoting protein synthesis and muscle growth (anabolic effects)
Maintaining bone mineral density through osteoblast stimulation
Regulating fat metabolism: promoting lipolysis and reducing visceral fat accumulation
Supporting brain function, neurogenesis, and cognitive performance
Modulating immune function and tissue repair

2. The IGF-1 Longevity Paradox

IGF-1 presents one of the most clinically nuanced biomarkers in longevity medicine because its relationship with health outcomes is not linear but J-shaped or U-shaped: both deficiency and excess are associated with increased disease risk and reduced lifespan.

Low IGF-1: Quality of Life vs Longevity

Interestingly, animal studies in multiple species show that reduced IGF-1 signaling extends maximum lifespan (Ames dwarf mice, Laron syndrome humans live longer on average)
However, low IGF-1 in adults severely impairs quality of life through sarcopenia, osteoporosis, cognitive decline, metabolic dysfunction, and fatigue
The human evidence suggests that extremely low IGF-1 in adults is associated with increased all-cause mortality despite the longevity paradox seen in animal models
Most longevity researchers distinguish between genetic low IGF-1 from birth (potentially protective) versus adult-acquired IGF-1 decline (generally harmful)

High IGF-1: Performance vs Risk

IGF-1 promotes cell proliferation and inhibits apoptosis; persistently elevated IGF-1 above 250 to 300 ng/mL is associated with increased prostate, breast, and colorectal cancer risk in epidemiological studies
Acromegaly (very high IGF-1 from pituitary GH excess) dramatically increases cardiovascular disease risk, diabetes risk, and mortality
High-normal IGF-1 within 200 to 250 ng/mL provides excellent anabolic support with less clear cancer risk elevation
Context matters: IGF-1 elevated from exercise and adequate protein has a different metabolic milieu than IGF-1 elevated from exogenous GH therapy

3. Standard Lab Reference Range

Population	Standard Range	Units
Adults ages 18 to 29	117 to 329	ng/mL
Adults ages 30 to 39	88 to 246	ng/mL
Adults ages 40 to 49	74 to 210	ng/mL
Adults ages 50 to 59	60 to 188	ng/mL
Adults ages 60 to 69	48 to 161	ng/mL

Standard ranges are age-adjusted, reflecting the normal decline in GH-IGF-1 axis activity with aging (somatopause). Functional medicine targets a middle range corresponding to the levels seen in younger, optimally healthy adults, rather than accepting age-related decline as inevitable.

4. Optimal Functional Medicine Range

IGF-1 Level	Functional Interpretation
120 to 200 ng/mL	Optimal: adequate anabolic support; muscle, bone, and cognitive health with manageable oncologic risk context
100 to 119 ng/mL	Low-normal: suboptimal anabolic support; evaluate GH axis, nutrition, sleep, and lifestyle
Below 100 ng/mL	Low: significant GH axis deficiency; sarcopenia and metabolic risk; comprehensive evaluation indicated
200 to 250 ng/mL	High-normal: excellent anabolic support; monitor for cancer history or family history; acceptable in athletic, high-protein, resistance-training context
Above 250 ng/mL	Elevated: investigate for exogenous GH use, pituitary pathology; evaluate cancer risk context

5. Symptoms Associated With Abnormal IGF-1

Low IGF-1

Progressive muscle loss (sarcopenia) and weakness
Increased visceral body fat despite unchanged diet
Reduced bone density and increased fracture risk
Fatigue and reduced exercise capacity
Poor recovery from exercise or illness
Cognitive difficulties, brain fog, and mood depression
Reduced immune function
Dry skin, thin hair, and reduced skin elasticity
Elevated cardiovascular risk markers (dyslipidemia)
Reduced quality of life and functional capacity

High IGF-1 (Acromegaly or Excess)

Enlargement of hands, feet, and facial features (acromegaly)
Joint pain and arthritis from cartilage overgrowth
Increased sweating and oily skin
Sleep apnea (soft tissue enlargement)
Insulin resistance and diabetes
Hypertension and cardiovascular disease risk
Carpal tunnel syndrome
Headaches from pituitary tumor pressure
In exogenous GH use: fluid retention, edema

6. What Causes Low IGF-1

Aging (somatopause): GH secretion declines progressively after the third decade; IGF-1 falls approximately 14% per decade; by age 60 to 70, IGF-1 is typically 30 to 50% of peak youthful levels
Growth hormone deficiency: pituitary adenoma, cranial irradiation, traumatic brain injury, or idiopathic GH deficiency; causes severely low IGF-1 with significant quality of life impairment
Protein or caloric undernutrition: IGF-1 production is highly sensitive to protein intake; very low protein diets (below 0.5g per kg per day) rapidly suppress IGF-1 regardless of GH status; this is the mechanism behind caloric restriction's IGF-1-lowering effects
Severe insulin resistance: hepatic GH receptor signaling is impaired in the setting of marked insulin resistance and fatty liver; a patient can have normal or elevated GH with paradoxically low IGF-1 from hepatic GH resistance
Hypothyroidism: thyroid hormone is required for normal GH pulsatility and hepatic IGF-1 production; untreated or undertreated hypothyroidism suppresses IGF-1
Liver disease: the liver is the primary site of IGF-1 synthesis; cirrhosis and significant hepatic dysfunction directly impair IGF-1 production
Sleep deprivation: 70 to 80% of daily GH secretion occurs during deep sleep stages; chronic poor sleep dramatically reduces GH pulses and downstream IGF-1
Chronic inflammatory illness: TNF-alpha and IL-6 directly suppress hepatic IGF-1 production and GH receptor signaling

7. How to Improve This Marker

Lifestyle

Resistance training: the single most potent natural stimulus for GH and IGF-1; compound movements (squats, deadlifts, bench press) with progressive overload produce the largest acute GH pulses and sustained IGF-1 elevation; 3 to 5 sessions per week
High-intensity interval training (HIIT): produces significant acute GH release; combine with resistance training for maximum IGF-1 support
Sleep optimization: 7 to 9 hours with attention to deep sleep quality; the cortisol-disrupting effect of poor sleep is one of the most impactful suppressors of GH pulsatility and IGF-1; blue light elimination, consistent bedtime, cool sleep environment
Reduce visceral fat: improves hepatic insulin sensitivity and GH receptor function; visceral adiposity is associated with lower IGF-1 through GH resistance
Intermittent fasting: produces GH spikes during fasting periods; carefully balanced with adequate protein on eating days to prevent protein-deficiency IGF-1 suppression

Nutrition

Adequate dietary protein: the most important nutritional variable for IGF-1; target 0.7 to 1.0g per pound of body weight daily; protein deficiency rapidly suppresses IGF-1 regardless of exercise status
Animal proteins (meat, fish, dairy, eggs) are the most potent IGF-1 stimulants; plant proteins raise IGF-1 less reliably due to amino acid profile and digestibility differences
Zinc: required cofactor for GH receptor signaling and IGF-1 production; deficiency measurably reduces IGF-1; 15 to 30mg zinc picolinate or bisglycinate daily
Vitamin D: deficiency is associated with reduced GH secretion and lower IGF-1; optimize to 60 to 80 ng/mL
Avoid extreme caloric restriction: very low calorie intake suppresses IGF-1 rapidly; ensure adequate overall energy intake alongside protein adequacy
Optimize thyroid function: subclinical hypothyroidism suppresses GH pulsatility and IGF-1 production

Medical Options

Growth hormone replacement therapy: for confirmed adult GH deficiency (low IGF-1 plus abnormal GH stimulation test); improves body composition, bone density, cardiovascular risk markers, and quality of life; requires specialist evaluation and prescription; monitoring IGF-1 to maintain within optimal range is essential
Peptide secretagogues: GHRH analogues (sermorelin, tesamorelin, CJC-1295) and GH secretagogues (ipamorelin, MK-677/ibutamoren) stimulate endogenous GH release rather than replacing GH directly; preserve pulsatile GH secretion pattern; used off-label in longevity medicine; physician supervision required
Address root causes: treat hypothyroidism, resolve insulin resistance, correct zinc and vitamin D deficiency, address sleep disorders; these interventions often raise IGF-1 significantly without direct GH manipulation
For high IGF-1 from pituitary source: somatostatin analogues (octreotide, lanreotide), GH receptor antagonist (pegvisomant), or pituitary surgery; specialist referral required

8. Related Lab Tests

IGFBP-3IGF-1 Binding Protein; GH Axis Context

→

DHEA-SParallel Biological Aging Marker

→

TSHThyroid Required for IGF-1 Production

→

Total TestosteroneSynergistic Anabolic Hormone

→

FerritinIron Deficiency Impairs GH-IGF-1 Axis

→

Vitamin DDeficiency Suppresses GH and IGF-1

→

9. When Testing Is Recommended

Adults over 40 experiencing progressive muscle loss, increased visceral fat, or declining exercise capacity despite adequate effort
Suspected adult growth hormone deficiency: severe fatigue, poor body composition, cognitive difficulties, and reduced quality of life despite normal thyroid and sex hormone status
Any comprehensive longevity or biological age assessment panel
Before and during GH secretagogue or GH replacement therapy to monitor response and avoid supraphysiologic levels
Evaluation of pituitary function; low IGF-1 may be the first sign of pituitary dysfunction
Suspected acromegaly: enlarging facial features, hands, feet, joint pain, and sleep apnea with progressive course
Nutrition assessment in patients with eating disorders, protein restriction, or severe caloric restriction
Monitoring in cancer survivors; IGF-1 interpretation requires careful oncologic context

10. Clinical Perspective

Clinical Perspective

IGF-1 is the biomarker that generates more nuanced conversations than almost any other in longevity medicine, because the science pulls in two directions simultaneously. On one hand, reduced IGF-1 signaling extends maximum lifespan in animal models, and there are human populations like Laron syndrome with very low IGF-1 who appear to have low cancer rates. On the other hand, in normally aging adults, low IGF-1 is consistently associated with sarcopenia, cognitive decline, cardiovascular disease, and reduced quality of life. The resolution I have arrived at is this: the goal in clinical practice is not the lowest possible IGF-1, it is the optimal IGF-1, which for most adults falls between 120 and 200 ng/mL. That range provides meaningful anabolic and metabolic support while avoiding the supraphysiologic levels associated with elevated cancer risk. How we get there matters enormously: resistance training, sleep, adequate protein, and optimized thyroid and testosterone are my preferred tools. GH peptides and GH therapy have a role in confirmed deficiency. But the lifestyle foundation comes first.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

11. Frequently Asked Questions

What is the optimal IGF-1 level?

In functional medicine, optimal IGF-1 for adults is approximately 120 to 200 ng/mL. This middle range avoids the sarcopenia, metabolic impairment, and reduced quality of life associated with IGF-1 below 100 ng/mL, while also avoiding the potential cancer-promoting effects associated with persistently elevated IGF-1 above 250 to 300 ng/mL. The optimal range shifts somewhat lower with advancing age and cancer history context.

What does low IGF-1 mean?

Low IGF-1 indicates reduced growth hormone axis activity and is associated with progressive muscle loss (sarcopenia), increased visceral fat, reduced bone density, fatigue, poor exercise recovery, cognitive difficulties, and reduced quality of life. Causes include aging (somatopause), GH deficiency, protein undernutrition, sleep deprivation, severe insulin resistance, hypothyroidism, liver disease, and chronic inflammation.

Is high IGF-1 associated with cancer?

The relationship is nuanced. Persistently supraphysiologic IGF-1 above 250 to 300 ng/mL is associated with increased prostate, breast, and colorectal cancer risk in epidemiological studies. However, IGF-1 within the functional medicine optimal range of 120 to 200 ng/mL has less clear cancer risk while providing well-established benefits for muscle mass, bone density, cognitive function, and metabolic health. Context matters: IGF-1 elevated from exercise and adequate protein carries a different risk profile than IGF-1 elevated from exogenous GH administration.

How do you naturally increase IGF-1?

Resistance training is the most potent natural stimulus. Adequate dietary protein (0.7 to 1.0g per pound of body weight daily) is the most critical nutritional factor; protein deficiency rapidly suppresses IGF-1 regardless of exercise. Sleep optimization (7 to 9 hours with quality deep sleep) drives GH pulsatility that produces IGF-1. Correcting zinc and vitamin D deficiency, treating hypothyroidism, and reducing visceral fat and insulin resistance also meaningfully raise IGF-1.

What is the relationship between IGF-1 and growth hormone?

Growth hormone (GH) is secreted by the pituitary in pulses, primarily during deep sleep. GH stimulates the liver to produce IGF-1. Because IGF-1 has a half-life of 12 to 15 hours while GH has a half-life of only 20 to 30 minutes, serum IGF-1 provides a far more stable and reproducible reflection of overall GH axis activity than measuring GH itself. IGF-1 mediates most of GH's anabolic effects on muscle, bone, and fat metabolism.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

IGF-1 declines with age. That decline is not inevitable.

Sarcopenia, visceral fat accumulation, and cognitive decline are partly driven by falling IGF-1 signaling. Schedule a consultation for a complete longevity and hormone panel.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.